June 9, 2010 -- At their recent Annual General Meeting the shareholders of Auris Medical AG elected Oliver Kubli to the company’s Board of Directors. Oliver Kubli is a Managing Director and member of the Board of Directors of Adamant Biomedical Investments AG, a Zurich based asset management company specializing in life science investments. He is Senior Portfolio Manager for the ZKB Pharma Vision Fund, Adamant Global Generika Fund and Adamant Healthcare Trends Fund. Prior to joining Adamant in 2008, Oliver Kubli held various management positions at Zürcher Kantonalbank (ZKB), Switzerland’s third largest bank. At ZKB, he was Senior Portfolio Manager for several life science funds with investments of more than CHF 1 billion and responsible for the global health care sector within the bank’s Asset Management Division. Oliver Kubli started his career in the financial sector in the ‘90s as financial analyst and portfolio manager with UBS and Swiss Re. He is a chartered financial analyst (CFA).
“Oliver Kubli has an intimate knowledge of the global life science industry”, said Thomas Meyer, founder and Managing Director of Auris Medical. “We are very pleased to have him on board and look forward to his contributions.”
About Auris Medical
Auris Medical is a Swiss biotechnology company developing specific pharmaceutical compounds for the prevention or treatment of inner ear disorders, an area of great unmet medical need. Around the world, many million people are suffering permanently from severe hearing loss and / or tinnitus, still lacking truly effective and safe treatments for their disorders. Auris Medical is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute sensorineural hearing loss (AM-111).
